VEETIDS '125'
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VEETIDS '125' (VEETIDS '125').
VEETIDS '125' (presumed to be a formulation containing penicillin V potassium) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
| Metabolism | Hepatic metabolism is minimal; primarily excreted unchanged in urine via renal tubular secretion. |
| Excretion | Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%. |
| Half-life | 2-4 hours in patients with normal renal function (CrCl >80 mL/min); prolonged to 20-40 hours in anuria. Clinical note: dosing interval must be adjusted based on creatinine clearance to avoid accumulation. |
| Protein binding | 10-20% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 0.3-0.5 L/kg (total body water), indicating limited tissue penetration except in kidneys and urine. |
| Bioavailability | Oral: 60-80% (variable due to first-pass metabolism); IM: 90-100% (complete). |
| Onset of Action | Oral: 30-60 minutes; IM: 10-20 minutes; IV: immediate (5-10 minutes for therapeutic levels). |
| Duration of Action | Oral/IM: 6-8 hours; IV: 4-6 hours. Clinical note: duration is dose-dependent and prolonged in renal impairment. |
125 mg orally twice daily for 5-10 days.
| Dosage form | FOR SOLUTION |
| Renal impairment | CrCl 30-50 mL/min: 125 mg once daily; CrCl 15-29 mL/min: 125 mg every 48 hours; CrCl <15 mL/min or hemodialysis: 125 mg every 48 hours. |
| Liver impairment | Child-Pugh A: 125 mg once daily; Child-Pugh B: 125 mg every 48 hours; Child-Pugh C: not recommended. |
| Pediatric use | For children ≥1 year: 2.5 mg/kg orally twice daily (max 125 mg/dose). |
| Geriatric use | Start at 125 mg once daily; increase to twice daily if tolerated and renal function adequate (CrCl >50 mL/min). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VEETIDS '125' (VEETIDS '125').
| Breastfeeding | Valproate is excreted into breast milk. M/P ratio approximately 0.05-0.1. Infant plasma levels are low (1-10% of maternal). Generally considered compatible with breastfeeding; monitor infant for sedation, thrombocytopenia, and liver function. |
| Teratogenic Risk | VEETIDS '125' contains valproate. Valproate is associated with a high risk of congenital malformations (neural tube defects, facial dysmorphism, cardiac defects) if used during the first trimester. Exposure in the second and third trimesters may cause fetal valproate syndrome, neurodevelopmental delays, and decreased IQ. Use is contraindicated in pregnancy unless no alternative. |
■ FDA Black Box Warning
No FDA black box warning identified for penicillin V potassium.
| Serious Effects |
["History of hypersensitivity to penicillins or cephalosporins","Patients with infectious mononucleosis (ampicillin-class penicillins specifically; contraindicated for penicillin V based on cross-reactivity risk)"]
| Precautions | ["Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported","Use with caution in patients with renal impairment","Prolonged use may result in overgrowth of nonsusceptible organisms","Clostridium difficile-associated diarrhea (CDAD) may occur"] |
Loading safety data…
| Fetal Monitoring | Maternal: Plasma valproate levels, liver function tests, platelet count, coagulation parameters. Fetal: Ultrasound for neural tube defects (α-fetoprotein), fetal echocardiogram, growth scans. Neurodevelopmental follow-up recommended postpartum. |
| Fertility Effects | Valproate may cause ovulatory dysfunction and polycystic ovary syndrome (PCOS)-like changes in women, leading to decreased fertility. Menstrual irregularities have been reported. Discontinuation may restore fertility. |